News | News By Subject | News by Disease News By Date | Search News

Dermatitis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Regeneron (REGN), Sanofi (SNY) Tout Phase III Dupixent Data     10/3/2016
Pfizer (PFE) Shows Off Final Data from Two Late-Stage Dermatitis Studies     7/13/2016
Regeneron (REGN) and Sanofi (SNY)'s Dermatitis Drug Meets Goals in Late-Stage Study     6/6/2016
Regeneron (REGN), Sanofi (SNY)'s Eczema Drug Clears Hurdles in Huge Late-Stage Studies     4/1/2016
Aquinox (AQXP)'s AQX-1125 Flunks Mid Stage Study for Patients With Atopic Dermatitis     11/3/2015
Anacor (ANAC) Hits Home Run with Crisaborole Phase III Trials, Predicts $1 Billion Potential Sales     7/15/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation     11/24/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Tames Eczema In Phase 2b Trial     7/10/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Hail Results of Dermatitis Study     3/4/2013
Anacor Pharmaceuticals, Inc. Reports Positive Preliminary Results From Two Safety Studies Of AN2728     2/7/2012
Galderma Pharma S.A. Announces Positive Phase 2b Results for Investigational Compound Targeting Redness of Rosacea     10/20/2011
Pfizer Inc. (PFE) Receives Approvable Letter from FDA for Dalbavancin     12/26/2007

News from Around the Web
Vanda (VNDA): Several Catalysts Coming Up     6/21/2017
Regeneron (REGN)'s New Drug Price Could Disappoint Everyone. Here's Why That's A Good Thing     3/29/2017
Hand Washing Focus In Hospitals Has Led To Rise In Worker Dermatitis, University of Manchester Study     2/13/2015
Brief Stress May Be Good For Your Skin, University of California, San Francisco (UCSF) Study     8/8/2014
Lower Occurrence of Atopic Dermatitis in Children Thanks to Farm Animals and Cats, University of Zurich Study     12/3/2010
Hold the Lime with Corona, May Cause Skin Reaction, Doctor Finds at Archives of Dermatology     10/19/2010
Drug Used To Treat Skin Conditions Is A Marine Pollutant, University of Gothenburg Study     3/24/2009
Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option For Skin Disorder, University of Minnesota Study     12/5/2008
Combination of Limes, Sun Can Result in 'Margarita Dermatitis'     8/16/2007
Glucocorticoid Plays Key Role In Skin Abnormalities Induced By Psychological Stress     12/1/2006
Steroid Lotion Effective For Eczema In Young Kids     5/1/2006
Cephalon, Inc. (CEPH) Drug A Victim Of ADHD Debate: Experts     3/30/2006
Kikkoman, Tohoku University Confirm That Tomato Extract Helps Heal Atopic Dermatitis     3/10/2006
Top 10 Causes Of Skin Allergy     3/9/2006
Delaying Solid Food By 6m Doesn't Prevent Allergy     2/21/2006

Press Releases
Sanofi (SNY) And Regeneron (REGN) Receive Positive CHMP Opinion For Dupixent (Dupilumab) To Treat Adult Patients With Moderate-To-Severe Atopic Dermatitis     7/21/2017
Spherix (SPEX) Announces Definitive Terms Reached To Acquire Controlling Interest In Hoth Therapeutics, A Biopharmaceutical Company Developing Its BioLexa Platform To Treat Skin Illness Such As Eczema     6/20/2017
LEO Pharma Starts Phase III Clinical Study For Tralokinumab In Atopic Dermatitis     6/15/2017
Ralexar Initiates Phase IIb Study Of ALX-101 In Patients With Atopic Dermatitis     5/31/2017
FDA Accepts Aclaris (ACRS)’ New Drug Application For Topical Treatment Of Seborrheic Keratosis, A Common Skin Condition     5/10/2017
Santalis Enrolls First U.S. Subject Into A Phase II Clinical Study Of Mild To Moderate Atopic Dermatitis     5/9/2017
Aclaris (ACRS) Completes Phase I Clinical Trial Of ATI-50001 For The Treatment Of Alopecia Universalis And Alopecia Totalis     5/5/2017
Sanofi (SNY) And Regeneron (REGN) Announce FDA Approval Of Dupixent (Dupilumab), The First Targeted Biologic Therapy For Adults With Moderate-To-Severe Atopic Dermatitis     3/28/2017
Sonoma Pharma (OCLS) Announces Results From Sebuderm Gel Study In Treatment Of Seborrheic Dermatitis     3/16/2017
Asana Biosciences Announces FDA Acceptance Of The IND Application For Its Novel SYK-JAK Inhibitor For Evaluation In Atopic Dermatitis     3/16/2017
Regeneron (REGN) And Sanofi (SNY) Announce Presentation Of Positive Data From Long-Term Pivotal Phase III CHRONOS Study Of DUPIXENT (Dupilumab) In Moderate-To-Severe Atopic Dermatitis     3/6/2017
LEO Pharma Announces Positive Results From Phase 2b Clinical Study For Tralokinumab In Atopic Dermatitis     3/3/2017
Signum Biosciences Receives $3.0M Phase IIB SBIR Grant For The Development Of SIG1451, A Novel Therapeutic For Atopic Dermatitis     2/15/2017
3M Company (MMM) Release: Revolutionary Skin Protectant Finally Gives Nurses the Power To Stop, Reverse And Prevent Incontinence Associated Dermatitis     2/1/2017
Menlo Therapeutics Starts Enrollment In Two Phase 2 Studies For Pruritus Associated With Atopic Dermatitis And Pruritus Following Burn Injury     1/9/2017